Pharmaceutical Manufacturing - Simulation of particulate processes
Verticaltalk Pharma e-Newsletter
Volume 3 No.2  2008
Project Management
A case for high performance
Natural Products - Indian Discovery
Verticaltalk Pharma - Media Pack
  Verticaltalk Pharma - News Roundup News Roundup
Nitec Pharma licenses Tarenflurbil for Inflammation and pain Sigma-Aldrich and MorphoSys collaborate for antibodies
Nitec Pharma licenses Tarenflurbil for Inflammation and pain Organogenesis acquires NanoMatrix, Inc.
  Verticaltalk Pharma  - Events Pharma Events
2nd Annual Pharmaceutical Leadership Summit, India, Nov 27 - 28 2007 MedChem India, India,
Mar 18 - 19 2008
Translational Drug Development in Asia 2007, China, Nov 27 - 29 2007 4th Pharmaceutical Industry in Thailand, SIngapore,
Mar 3 - Apr 1 2008
 
  Verticaltalk Pharma - Press Releases Pharma Press Releases
FDA To Continue Its Review of Requests for Release of Clinical Hold on alvimopan (Entereg(R)) CollaGenex Pharmaceuticals Signs Merger Agreement with Galderma Pharma S.A.
FDA To Continue Its Review of Requests for Release of Clinical Hold on alvimopan (Entereg(R)) ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
Current Issue   |   Archives   |   Advertise
In this issue of Verticaltalk Pharma
Verticaltalk Pharma - Articles Article
     
  Project Management: A case for high performance
Timothy Stockert, Principal & Owner, INNOVA Group, Inc., USA

 
As increased competitiveness paves its way in the global arena, all market places, whether pharma, automotive or manufacturing are undergoing continual changes to cut cost and increase efficiency. This article brings with it the challenges faced by individual companies to tailor their project managements and stay ahead of the competition.
Full Text | More Articles
 
Verticaltalk Pharma - Interview Interview
   
GE Healthcare Expands its Life Sciences Business
Peter Enrenheim, President & CEO, Life Sciences, GE Healthcare, UK
Our current business focus and strengths are in the areas of bioprocessing, proteins, cellular analysis, cell handling and tools for cell therapy. Our strategic intent is to add adjacent technologies or applications which can add value to the overall customer solutions we provide.
Full Text | More Interviews
Verticaltalk Pharma - Bookshelf Pharma Bookshelf
     
 
Statistical Issues in Drug Development (Statistics in Practice)
Author(s) - Stephen Senn

Drug development is the process of finding and producing therapeutically useful pharmaceuticals, turning them into safe and effective medicine, and producing reliable information regarding the appropriate dosage and dosing intervals. With regulatory authorities demanding increasingly higher standards in such developments, statistics has become an intrinsic and critical element in the design and conduct of drug development programmes.
More Books
Verticaltalk Pharma - Research Insights Research Insight
     
 
 
We postulated that pharmacological targeting of putative stromal support functions, in particular those of cancer-associated fibroblasts, could have therapeutic utility, and sought to assess the possibility in a pre-clinical setting.
  Full Text | More Insights
   
Verticaltalk Pharma - Projects Projects Verticaltalk Pharma - TechnoTrends TechnoTrends Verticaltalk Pharma - Industry Reports Industry Reports
Teva to set up API Facility in India

Teva is planning to set up an Active Pharmaceutical Ingredient in the country. The project is expected to be completed in the next two years.

PTR to Build Stem Cell Manufacturing Plant

Pahang Technology Resources is teaming up with BCRO Stem Cell Xenotransplantation to jointly build a stem cell manufacturing plant in Malayasia.
More Projects
Biochips to Simplify Drug Development Safety Studies

The Biochips consist of Metachip and Datachip. Metachip is a glass slide dotted with 20 nanolitre droplets of a solution with human enzymes.

Clontech Laboratories Develops ProteoTuner Systems

The ability to quickly and directly control protein levels with the ProteoTuner systems is a novel tool for studying even transient effects of the protein of interest.
More TechnoTrends
 
The Pharmaceutical Company Outlook to 2012
A Report by Datamonitor

The pharmaceutical industry faces a muted outlook with ethical sales forecast to grow at a 2006–12 CAGR of only 3.2%. However, behind this disappointing industry average figure there are strategic segments of the market that offer companies double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening. The Big Pharma peer set is forecast to see sales increase at a 2.3% CAGR over 2006–12.
 
Send this newsletter to a friend or colleague.
Your Name: Friend's Name: Email:
You are receiving this email because you are either a registered member or requested for a newsletter from Verticaltalk Pharma.
To SUBSCRIBE
QUESTIONS: For questions or assistance, please contact our Customer Support Staff : verticaltalkpharma@ochre-media.com
PRIVACY: View our Privacy Policy
Copyright © 2008 Ochre Media Private Limited. All rights reserved.
Indian Pharma - The Discovery Metamorphosis IMS